Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore

Neurology

Volumn 71, Issue 21, 2008, Pages 1727-1732

  Lin, C H ^a   Tan, E K ^b,d   Chen, M L ^a   Tan, L C ^b   Lim, H Q ^b   Chen, G S ^c   Wu, R M ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^c PROVIDENCE UNIVERSITY   (Taiwan)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; ALANINE; ATP13A2 PROTEIN, HUMAN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; THREONINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; ATP13A2 GENE; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNICITY; EXON; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PHENOTYPE; PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DOMAIN; RISK FACTOR; SCREENING; SINGAPORE; TAIWAN; VALIDITY; ASIAN; CHEMICAL STRUCTURE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; METHODOLOGY; MIDDLE AGED; MUTATION; PATHOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE; ASIAN CONTINENTAL ANCESTRY GROUP; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MODELS, MOLECULAR; MUTATION; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PROTON-TRANSLOCATING ATPASES; SINGAPORE; TAIWAN; THREONINE; YOUNG ADULT;

EID: 58149217157     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000335167.72412.68     Document Type: Article

References (24)

1. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608.
2. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-452.
3. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
4. Ramirez A, Heimbach A, Grundemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006;38:1184-1191.
5. Valente EM, Salvi S, Ialongo T, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004;56:336-341.
6. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607.
7. Williams DR, Hadeed A, al-Din AS, Wreikat AL, Lees AJ. Kufor Rakeb disease: autosomal recessive, levodoparesponsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 2005; 20:1264-1271.
8. Najim al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 1994;89:347-352.
9. Di Fonzo A, Chien HF, Socal M, et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 2007;68:1557-1562.
10. Lockhart PJ, Bounds R, Hulihan M, et al. Lack of mutations in DJ-1 in a cohort of Taiwanese ethnic Chinese with early-onset parkinsonism. Mov Disord 2004;19:1065-1069.
11. Wu RM, Bounds R, Lincoln S, et al. Parkin mutations and early-onset parkinsonism in a Taiwanese cohort. Arch Neurol 2005;62:82-87.
12. Lee MJ MI, Lin CH, Tzen KY, et al. Genotype-Phenotype correlates in Taiwanese patients with early-onset recessive parkinsonism. Mov Disord 2008 (in press).
13. Tan EK, Zhao Y, Skipper L, et al. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet 2007;120: 857-863.
14. Farrer MJ, Stone JT, Lin CH, et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat Disord 2007;13:89-92.
15. Ross OA, Wu YR, Lee MC, et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neu-rol 2008 (in press).
16. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
18. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 1984; 32:489-502.
19. Wu RM, Shan DE, Sun CM, et al. Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations. Mov Disord 2002;17:670-675.
20. Spencer WE, Christensen MJ. Multiplex relative RT-PCR method for verification of differential gene expression. Biotechniques 1999; 27:1044-1046, 1048-1050, 1052.
21. Kuhlbrandt W. Biology, structure and mechanism of P-type ATPases. Nat Rev Mol Cell Biol 2004;5:282-295.
22. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007;6:652-662.
23. Abou-Sleiman PM, Muqit MM, McDonald NQ, et al. A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol 2006;60:414-419.
24. Hedrich K, Hagenah J, Djarmati A, et al. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? Arch Neurol 2006;63:833-838.